Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Oct 10, 2012
U-M researchers discuss how a recent outbreak of fungal meningitis distributed through spinal steroid injections has once again brought to light the difficulty of compounding pharmaceutical companies to maintain quality control over their products. Professors Kotov and Wang explain how a combination of better oversight and easier testing methods could ultimately help prevent issues like this in the future.
Nicholas A. Kotov (http://che.engin.umich.edu/people/kot...) is the Joseph B. and Florence C. Cejka Professor of Engineering. He is committed to engaging in the "most creative, forward looking, and unorthodox scientific and engineering discoveries." He runs The Kotov Lab (http://www.umkotov.com/) at the University of Michigan.